Abstract Library

#3034 Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is ≥ 10%?

Introduction: The antiproliferative effect of first-line long acting somatostatin analogs (SSA) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) was shown in the PROMID and the CLARINET trials. Efficacy data in pancreatic NETs (PanNETs) with Ki-67 ≥ 10% are limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Merola E

Authors: Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pelle E,

Keywords: Pancreatic NET, Somatostatin Analogs, Grade 2 and 3, Safety, Efficacy,

#2152 Sequential Therapies in Well-Differentiated Gastrointestinal Neuroendocrine Tumors G3 (NET G3): Platinum-Based vs. Platinum-Free Regimens

Introduction: Well-differentiated NET G3 show a longer clinical course than NEC G3, preliminary data indicate they respond poorly to platinum-based therapies.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Dal Buono A

Authors: Dal Buono A, Merola E, Delle Fave G, Wiedenmann B, Pavel M,

Keywords: well-differentiated, platinum, streptozotocin,

#2137 Evaluation of Multidisciplinary Tumor Board Decisions in the Management of Neuroendocrine Tumors: Impact of Expert Centers

Introduction: ENETS requires Centers of Excellence to discuss all new gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients in a multidisciplinary tumor board (MDT) but the true value of the MDT has never been assessed

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Zandee W

Authors: Zandee W, Merola E, de Mestier L, Klümpen H, Geboes K,

Keywords: Standard of Care, Multidisciplinary Tumor Board, Quality of Care,

#2046 Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference?

Introduction: A proportion of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) referred to NEN expert centers need a histopathological revision.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Merola E

Authors: Merola E, Zandee W, de Mestier L, Klümpen H, Geboes K,

Keywords: neuroendocrine, NET referral centers, histopathological revision, patient management,

#1577 Peritoneal Carcinomatosis in Digestive Neuroendocrine Neoplasms: Complications and Response to Therapy

Introduction: Peritoneal carcinomatosis (PC) is present in 10-30% of digestive neuroendocrine neoplasms (DNENs), affecting prognosis and quality of life with recurrent abdominal pain and bowel obstruction

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: merola e

Authors: Merola E, Prasad V, Pascher A, Denecke T, Arsenic R,

Keywords: peritoneal carcinomatosis, neuroendocrine, bowel obstruction,